Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Access to immunotherapy for stage IV pancreatic cancer varies significantly by race and socioeconomic status. Interventions are needed to ensure equitable access to this vital treatment for all patients.
Area Of Science
- Oncology
- Cancer Research
- Immunotherapy
Background
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with low survival rates.
- Immunotherapy offers promise but faces challenges in PDAC treatment.
- Most PDAC patients are diagnosed at advanced stages, limiting treatment options.
Purpose Of The Study
- To analyze disparities in immunotherapy utilization for stage IV PDAC.
- To investigate the impact of race, insurance, and socioeconomic factors on treatment access.
Main Methods
- Analysis of National Cancer Database (NCDB) data from 2010-2017.
- Inclusion of 109,663 patients diagnosed with stage IV PDAC.
- Logistic regression analyses to assess factors influencing immunotherapy receipt.
Main Results
- Only 0.38% of stage IV PDAC patients received immunotherapy.
- Immunotherapy recipients were more likely to be white, have private insurance, and higher income.
- Black patients and those with lower income had significantly lower odds of receiving immunotherapy.
Conclusions
- Significant disparities exist in immunotherapy access for stage IV PDAC.
- Race, socioeconomic status, and location impact treatment equity.
- Interventions are crucial to promote equitable access to immunotherapy for PDAC patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...